MapLight Therapeutics, Inc. (MPLT) saw its stock price soar 5.11% during intraday trading on Thursday, marking a significant upward movement for the biopharmaceutical company.
The surge appears to be driven by positive analyst coverage, as Craig-Hallum initiated coverage of MapLight Therapeutics with a Buy rating and set a price target of $43. Such bullish analyst initiations often generate increased investor interest and buying activity in the stock.